A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2022
This is a Phase II Randomized Window of Opportunity Trial Evaluating Clinical and Biological effects of PRMT5 inhibitor, GSK3326595, in Early Stage Breast Cancer
Epistemonikos ID: ef9f1deffdcb962bf7eb9f9d73b43213d7072c28
First added on: Oct 02, 2023